uniQure N.V. (NASDAQ:QURE) Receives $58.33 Average PT from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.3333.

A number of research firms have recently weighed in on QURE. Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a research report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday, February 10th. Chardan Capital restated a “buy” rating and set a $53.00 price objective on shares of uniQure in a report on Thursday, December 4th. Finally, Stifel Nicolaus dropped their target price on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th.

uniQure Trading Up 4.1%

uniQure stock opened at $24.40 on Friday. The stock has a 50-day moving average price of $23.52 and a 200 day moving average price of $29.26. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The stock has a market cap of $1.52 billion, a PE ratio of -5.56 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

Insider Activity

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. Private Trust Co. NA purchased a new position in shares of uniQure in the 3rd quarter worth $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 627 shares during the period. Finally, Ensign Peak Advisors Inc lifted its stake in shares of uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Technical strength: uniQure was noted as meeting an “80-plus relative strength rating” — a bullish technical signal that can attract momentum traders and support short-term buying interest. Article Title
• Neutral Sentiment: Earnings catalyst: Reports indicate uniQure was scheduled to release quarterly results this week — an event that can swing the stock either way depending on clinical updates, revenue, guidance or cost items. Investors should treat the print as a near-term catalyst. Article Title
• Negative Sentiment: Wave of securities class‑action notices: Multiple plaintiff firms (including Kessler Topaz, Levi & Korsinsky, Rosen, Pomerantz, Berger Montague, Faruqi, Bernstein Liebhard and others) have filed or publicized securities‑fraud suits alleging misstatements for investors who bought shares between Sept. 24, 2025 and Oct. 31, 2025; many notices cite an April 13, 2026 lead‑plaintiff deadline. This cluster of litigation notices increases legal and reputational risk, can pressure the stock via investor selloffs and may lead to future settlements or costs (magnitude uncertain). Representative filings and notices: Article Title Article Title Article Title

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.